Recent advances in the systemic therapy of cancer

被引：0

作者：

Harrington, J. ^{[1
]}

Evans, T. R. J. ^{[2
]}

机构：

[1] Beatson West Scotland Canc Ctr, Med Oncol, Glasgow, Lanark, Scotland

[2] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Translat Canc Res, Glasgow, Lanark, Scotland

来源：

JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH | 2009年 / 39卷 / 02期

关键词：

Angiogenesis; apoptosis; cell cycle regulation; cellular senescence; monoclonal antibodies; tyrosine kinase;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The current generation of anti-cancer agents, often referred to as molecularly targeted therapies, are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. This review focuses on these therapies, particularly as many of the drugs concerned have received considerable attention in the popular media.

引用

页码：134 / 137

页数：4

共 13 条

[11] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

[12] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[13] SIGNAL TRANSDUCTION BY RECEPTORS WITH TYROSINE KINASE-ACTIVITY [J].

ULLRICH, A ;

SCHLESSINGER, J .

CELL, 1990, 61 (02) :203-212

← 1 2 →